ITB Med is pioneering a novel therapy aimed at transforming the field of transplantation by addressing the lifelong need for immunosuppression that typically follows organ transplants. Their innovative approach seeks to induce transplantation tolerance, which could allow patients to live without the burden of anti-rejection medications. This therapy has already shown promising results, as evidenced by the case of Jennifer Searl, the first HLA-mismatched patient to successfully receive a kidney transplant with induced tolerance, allowing her to live for over 15 years without immunosuppressive drugs. The potential benefits of this therapy include improved patient outcomes, enhanced quality of life, and reduced healthcare costs.

The company’s research and development pipeline encompasses a variety of projects across multiple focus areas, including kidney and liver transplantation, xenotransplantation, and autoimmune conditions. ITB Med is currently advancing several therapies through various phases of clinical development, from IND-enabling studies to pivotal trials. Their portfolio includes initiatives aimed at achieving tolerance in organ transplantation, preventing graft-versus-host disease (GVHD) in bone marrow transplants, and exploring new-onset remission strategies for autoimmune diseases like Type-1 diabetes and amyotrophic lateral sclerosis. This comprehensive approach underscores ITB Med's commitment to revolutionizing transplant medicine and improving patient care.

United States

ITB-MED is developing the proprietary antagonistic CD2-directed monoclonal antibody, TCD601 (siplizumab), for several indications. The lifelong need for immunosuppression after transplantation negatively affects both patient health and the transplanted organ. Clinical Trials are being executed globally with a particular focus on improving patient health post-transplantation.

ITB Med

Company Details